KTTA Stock Chart & Stats
$0.74
-$0.19(-6.35%)
At close: 4:00 PM EST
$0.74
-$0.19(-6.35%)
Day’s Range― - ―
52-Week Range$0.28 - $2.06
Previous CloseN/A
Volume25.24K
Average Volume (3M)98.68K
Market Cap
$18.94M
Enterprise Value-$46.66M
Total Cash (Recent Filing)$50.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,414,448
10 Day Avg. Volume100,274
30 Day Avg. Volume98,683
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit147.90
Enterprise Value/Ebitda2.18
Forecast
1Y Price Target
$3.00Price Target Upside305.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
KTTA FAQ
What was Pasithea Therapeutics Corp’s price range in the past 12 months?
Pasithea Therapeutics Corp lowest stock price was $0.28 and its highest was $2.06 in the past 12 months.
What is Pasithea Therapeutics Corp’s market cap?
Pasithea Therapeutics Corp’s market cap is $18.94M.
When is Pasithea Therapeutics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pasithea Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Pasithea Therapeutics Corp overvalued?
According to Wall Street analysts Pasithea Therapeutics Corp’s price is currently Undervalued.
Does Pasithea Therapeutics Corp pay dividends?
Pasithea Therapeutics Corp does not currently pay dividends.
What is Pasithea Therapeutics Corp’s EPS estimate?
Pasithea Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pasithea Therapeutics Corp have?
Pasithea Therapeutics Corp has 33,414,448 shares outstanding.
What happened to Pasithea Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pasithea Therapeutics Corp?
Currently, no hedge funds are holding shares in KTTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pasithea Therapeutics Corp
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
KTTA Stock 12 Month Forecast
Average Price Target
$3.00
▲(305.41% Upside)
Technical Analysis
Ownership Overview
12.59% Insiders
0.31% Mutual Funds
26.84% Other Institutional Investors
57.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---







